124 related articles for article (PubMed ID: 35791674)
21. Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer.
Sheikhshabani SH; Modarres P; Ghafouri-Fard S; Amini-Farsani Z; Khodaee L; Shaygan N; Amini-Farsani Z; Omrani MD
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1970. PubMed ID: 38351531
[TBL] [Abstract][Full Text] [Related]
22. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer.
Wang W; Zhao M; Cui L; Ren Y; Zhang J; Chen J; Jia L; Zhang J; Yang J; Chen G; Ashby CR; Wu C; Chen ZS; Wang L
Mol Cancer; 2020 Sep; 19(1):134. PubMed ID: 32878625
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
25. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines.
Song L; Cui Z; Guo X
Acta Biochim Biophys Sin (Shanghai); 2020 Sep; 52(9):944-953. PubMed ID: 32716023
[TBL] [Abstract][Full Text] [Related]
27. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
28. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer.
Xu YH; Tu JR; Zhao TT; Xie SG; Tang SB
Int J Oncol; 2019 Jan; 54(1):295-305. PubMed ID: 30431074
[TBL] [Abstract][Full Text] [Related]
30. LINC01140 inhibits nonsmall cell lung cancer progression and cisplatin resistance through the miR-4742-5p/TACC1 axis.
Wang Y; Li M; Zhang L; Chen Y; Ha M
J Biochem Mol Toxicol; 2022 Jul; 36(7):e23048. PubMed ID: 35307914
[TBL] [Abstract][Full Text] [Related]
31. FIGNL1-containing protein complex is required for efficient homologous recombination repair.
Yuan J; Chen J
Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10640-5. PubMed ID: 23754376
[TBL] [Abstract][Full Text] [Related]
32. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
[TBL] [Abstract][Full Text] [Related]
34. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
Zhong T; Zhang J; Liu X; Li H
Cell Oncol (Dordr); 2023 Oct; 46(5):1493-1507. PubMed ID: 37219768
[TBL] [Abstract][Full Text] [Related]
35. Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519a.
Tang H; Han X; Li M; Li T; Hao Y
Biochimie; 2019 Jul; 162():134-143. PubMed ID: 31029744
[TBL] [Abstract][Full Text] [Related]
36. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
Hu C; Zhang M; Moses N; Hu CL; Polin L; Chen W; Jang H; Heyza J; Malysa A; Caruso JA; Xiang S; Patrick S; Stemmer P; Lou Z; Bai W; Wang C; Bepler G; Zhang XM
Cell Death Dis; 2020 May; 11(5):328. PubMed ID: 32382008
[TBL] [Abstract][Full Text] [Related]
37. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
[TBL] [Abstract][Full Text] [Related]
38. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
[TBL] [Abstract][Full Text] [Related]
39. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
40. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
